Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial

Background: We present results of a 24-week comparative study of the effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin vs. the sulfonylurea glimepiride, by baseline body mass index (BMI), in patients with type 2 diabetes and chronic heart failure. Methods: We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sezai, Akira, Tanaka, Atsushi, Imai, Takumi, Kida, Keisuke, Sekino, Hisakuni, Murohara, Toyoaki, Sata, Masataka, Suzuki, Norio, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312925/
https://www.ncbi.nlm.nih.gov/pubmed/35884961
http://dx.doi.org/10.3390/biomedicines10071656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312925/
https://www.ncbi.nlm.nih.gov/pubmed/35884961
http://dx.doi.org/10.3390/biomedicines10071656

Ejemplares similares